Isabelle van Rycke
Algemeen Directeur bij Upsa Belgium SA
Profiel
Ms. Isabelle van Rycke is a Chairman & Chief Executive Officer at UPSA SAS and a Co-Managing Director & Director at UPSA Belgium SA. She is on the Board of Directors at UPSA Belgium SA.
Actieve functies van Isabelle van Rycke
| Bedrijven | Functie | Begin |
|---|---|---|
Upsa Belgium SA
 Upsa Belgium SA Medical DistributorsDistribution Services UPSA Belgium SA wholesales pharmaceutical products. The private company is based in Etterbeek, Belgium. The CEOs are Isabelle van Rycke, Jun Kuroda. The Belgian company was founded in 2019. | Algemeen Directeur | 01-07-2021 |
UPSA SAS
 UPSA SAS Pharmaceuticals: MajorHealth Technology Part of Taisho Pharmaceutical Holdings Co., Ltd., UPSA SAS is a pharmaceutical laboratory that specializes in effervescence, pain treatment, ENT disorders, vitality, digestion, and sleep quality. The company is based in Rueil-Malmaison, France. The CEOs of the French company are Anthony Lallier and Isabelle van Rycke. UPSA was acquired by Taisho Pharmaceutical Co., Ltd. from Bristol Myers Squibb Co. on July 01, 2019 for $1,465.24 million. | Algemeen Directeur | 01-05-2021 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Upsa Belgium SA
Upsa Belgium SA Medical DistributorsDistribution Services UPSA Belgium SA wholesales pharmaceutical products. The private company is based in Etterbeek, Belgium. The CEOs are Isabelle van Rycke, Jun Kuroda. The Belgian company was founded in 2019. | Distribution Services |
UPSA SAS
UPSA SAS Pharmaceuticals: MajorHealth Technology Part of Taisho Pharmaceutical Holdings Co., Ltd., UPSA SAS is a pharmaceutical laboratory that specializes in effervescence, pain treatment, ENT disorders, vitality, digestion, and sleep quality. The company is based in Rueil-Malmaison, France. The CEOs of the French company are Anthony Lallier and Isabelle van Rycke. UPSA was acquired by Taisho Pharmaceutical Co., Ltd. from Bristol Myers Squibb Co. on July 01, 2019 for $1,465.24 million. | Health Technology |
